Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Bullboard Posts
Post by Riverfolkon Mar 31, 2020 9:04am
87 Views
Post# 30863372

New Video Showing Metablok Reducing Lung Inflammation in an

New Video Showing Metablok Reducing Lung Inflammation in an

2020-03-31 07:36 ET - News Release

 

TORONTO, March 31, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today released a new video on its website showing the efficacy of its lead drug candidate Metablok in reducing neutrophil recruitment in a mouse model of lung inflammation.

The new video can be viewed at the Arch Biopartners website here (click to view).

The Company also announced today it is planning the start of a Phase II human trial for Metablok to target lung inflammation in COVID-19 patients by the summer of this year.  Arch recently disclosed that the Phase I human trial for Metablok (LSALT peptide) safely concluded dosing.

In the absence of a vaccine to prevent COVID-19 infection, a treatment to manage the lung inflammation experienced in the most severe cases can reduce the numbers of people admitted to intensive care units, lower the demand for hospital ventilators and improve survival rates.

The Company continues to organize the Phase II trial involving COVID-19 patients. “Normally, a human trial takes several months or longer to prepare. In this unusual and challenging time, we are working to organize a Phase II human trial in a matter of weeks. We are impressed with our team’s rapid progress to date,” said Richard Muruve, CEO of Arch Biopartners

Bullboard Posts